BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Morrisette T, Van Matre AG, Miller MA, Mueller SW, Bajrovic V, Abidi MZ, Benamu E, Kaiser JN, Barber GR, Chase S, Tobin J, Fish DN, Gutman JA. Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population. Biol Blood Marrow Transplant 2019;25:2091-7. [PMID: 31255741 DOI: 10.1016/j.bbmt.2019.06.021] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 van Prehn J, Reigadas E, Vogelzang EH, Bouza E, Hristea A, Guery B, Krutova M, Norén T, Allerberger F, Coia J, Goorhuis A, van Rossen TM, Ooijevaar RE, Burns K, Scharvik Olesen BR, Tschudin-Sutter S, Wilcox MH, Vehreschild M, Fitzpatrick F, Kuijper EJ; guideline committee of the European Study Group on Clostridioides difficile. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect 2021:S1198-743X(21)00568-1. [PMID: 34678515 DOI: 10.1016/j.cmi.2021.09.038] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, Stollman NH. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol 2021;116:1124-47. [PMID: 34003176 DOI: 10.14309/ajg.0000000000001278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Tariq R, Laguio-Vila M, Tahir MW, Orenstein R, Pardi DS, Khanna S. Efficacy of oral vancomycin prophylaxis for prevention of Clostridioides difficile infection: a systematic review and meta-analysis. Therap Adv Gastroenterol 2021;14:1756284821994046. [PMID: 33747124 DOI: 10.1177/1756284821994046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Khanna S. My Treatment Approach to Clostridioides difficile Infection. Mayo Clin Proc 2021;96:2192-204. [PMID: 34175104 DOI: 10.1016/j.mayocp.2021.03.033] [Reference Citation Analysis]
5 Babar S, El Kurdi B, El Iskandarani M, Haddad I, Imam Z, Alomari M, Myers J, Moorman J. Oral vancomycin prophylaxis for the prevention of Clostridium difficile infection: A systematic review and meta-analysis. Infect Control Hosp Epidemiol 2020;41:1302-9. [PMID: 32594929 DOI: 10.1017/ice.2020.277] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
6 Reigadas E, van Prehn J, Falcone M, Fitzpatrick F, Vehreschild MJGT, Kuijper EJ, Bouza E; European Society of Clinical Microbiology and Infectious Diseases Study Group on Clostridioides difficile (ESGCD) and Study Group for Host and Microbiota interaction (ESGHAMI). How to: prophylactic interventions for prevention of Clostridioides difficile infection. Clin Microbiol Infect 2021:S1198-743X(21)00368-2. [PMID: 34245901 DOI: 10.1016/j.cmi.2021.06.037] [Reference Citation Analysis]
7 Non LR, Ince D. Infectious Gastroenteritis in Transplant Patients. Gastroenterol Clin North Am 2021;50:415-30. [PMID: 34024449 DOI: 10.1016/j.gtc.2021.02.013] [Reference Citation Analysis]
8 Nix CD, Messer WB, Hale ML, Lewis JS 2nd, Strasfeld LM. Impact of a Clostridioides Difficile Testing Computerized Clinical Decision Support Tool on an Adult Stem Cell Transplantation and Hematologic Malignancies Unit. Transplant Cell Ther 2021;27:94.e1-5. [PMID: 33045386 DOI: 10.1016/j.bbmt.2020.10.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Poylin V, Hawkins AT, Bhama AR, Boutros M, Lightner AL, Khanna S, Paquette IM, Feingold DL; Prepared by the Clinical Practice Guidelines Committee of The American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Clostridioides difficile Infection. Dis Colon Rectum 2021;64:650-68. [PMID: 33769319 DOI: 10.1097/DCR.0000000000002047] [Reference Citation Analysis]
10 Bogdanová K, Doubravská L, Vágnerová I, Hricová K, Pudová V, Röderová M, Papajk J, Uvízl R, Langová K, Kolář M. Clostridioides difficile and Vancomycin-Resistant Enterococci in COVID-19 Patients with Severe Pneumonia. Life (Basel) 2021;11:1127. [PMID: 34833003 DOI: 10.3390/life11111127] [Reference Citation Analysis]
11 Wong D, Nanda N. Clostridium difficile disease in solid organ transplant recipients: a recommended treatment paradigm. Curr Opin Organ Transplant 2020;25:357-63. [PMID: 32618715 DOI: 10.1097/MOT.0000000000000778] [Reference Citation Analysis]
12 Austin K, Sweet M, Likar E, LaSala PR, Murray A, Wen S, Ross KG, Kanate AS, Veltri L, Matuga R, Cumpston A. Prospective assessment of Clostridioides (formerly Clostridium) difficile colonization and acquisition in hematopoietic stem cell transplant patients. Transpl Infect Dis 2020;22:e13438. [PMID: 32767807 DOI: 10.1111/tid.13438] [Reference Citation Analysis]
13 Keats KR, Stitt TM, Chastain DB, Jivan BP, Matznick E, Waller JL, Clemmons AB. Evaluating Clostridioides difficile infection (CDI) treatment duration in hematology/oncology patients receiving concurrent non-CDI antibiotics. J Oncol Pharm Pract 2021;:1078155221998735. [PMID: 33663290 DOI: 10.1177/1078155221998735] [Reference Citation Analysis]
14 Pillinger KE, Bouchard J, Withers ST, Mediwala K, McGee EU, Gibson GM, Bland CM, Bookstaver PB. Inpatient Antibiotic Stewardship Interventions in the Adult Oncology and Hematopoietic Stem Cell Transplant Population: A Review of the Literature. Ann Pharmacother 2020;54:594-610. [PMID: 31771337 DOI: 10.1177/1060028019890886] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]